Shield Therapeutics raised £25m (gross) with up to £4.2m possible via an Open Offer to provide adequate funding to launch Accrufer in the US and sufficient working capital to reach EBITDA breakeven, which is anticipated in 15-18 months. With the prospect of reaching $100m of US revenues and c.$45-50m of EBITDA in 3-4 years, the return on investment is potentially substantial. It is also underpinned by the value of royalty income from sales in Europe through Norgine and the prospect of approval a ....
01 Mar 2021
Shield Therapeutics - £25m fundraise with Open Offer up to £4.2m
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - £25m fundraise with Open Offer up to £4.2m
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
01 Mar 2021 -
Author:
Mark Brewer | Cavendish Research -
Pages:
21
Shield Therapeutics raised £25m (gross) with up to £4.2m possible via an Open Offer to provide adequate funding to launch Accrufer in the US and sufficient working capital to reach EBITDA breakeven, which is anticipated in 15-18 months. With the prospect of reaching $100m of US revenues and c.$45-50m of EBITDA in 3-4 years, the return on investment is potentially substantial. It is also underpinned by the value of royalty income from sales in Europe through Norgine and the prospect of approval a ....